Cargando…

Anti-atherosclerotic effects of the glucagon-like peptide-1 (GLP-1) based therapies in patients with type 2 Diabetes Mellitus: A meta-analysis

This study assessed the effect of GLP-1 based therapies on atherosclerotic markers in type 2 diabetes patients. 31 studies were selected to obtain data after multiple database searches and following inclusion and exclusion criteria. Age and BMI of the participants of longitudinal studies were 59.8 ±...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Xiaoyan, Jia, Hetang, Jiang, Yuebo, Wang, Liang, Zhang, Yan, Mu, Yiming, Liu, Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4481643/
https://www.ncbi.nlm.nih.gov/pubmed/26111974
http://dx.doi.org/10.1038/srep10202
_version_ 1782378301166190592
author Song, Xiaoyan
Jia, Hetang
Jiang, Yuebo
Wang, Liang
Zhang, Yan
Mu, Yiming
Liu, Yu
author_facet Song, Xiaoyan
Jia, Hetang
Jiang, Yuebo
Wang, Liang
Zhang, Yan
Mu, Yiming
Liu, Yu
author_sort Song, Xiaoyan
collection PubMed
description This study assessed the effect of GLP-1 based therapies on atherosclerotic markers in type 2 diabetes patients. 31 studies were selected to obtain data after multiple database searches and following inclusion and exclusion criteria. Age and BMI of the participants of longitudinal studies were 59.8 ± 8.3 years and 29.2 ± 5.7 kg/m(2) (Mean±SD). Average duration of GLP-1 based therapies was 20.5 weeks. Percent flow-mediated diameter (%FMD) did not change from baseline significantly but when compared to controls, %FMD increased non-significantly following GLP-1-based therapies (1.65 [−0.89, 4.18]; P = 0.2; REM) in longitudinal studies and increased significantly in cross sectional studies (2.58 [1.68, 3.53]; P < 0.00001). Intima media thickness decreased statistically non-significantly by the GLP-1 based therapies. GLP-1 based therapies led to statistically significant reductions in the serum levels of brain natriuretic peptide (−40.16 [−51.50, −28.81]; P < 0.0001; REM), high sensitivity c-reactive protein (−0.27 [−0.48, −0.07]; P = 0.009), plasminogen activator inhibitor-1 (−12.90 [−25.98, 0.18]; P=0.05), total cholesterol (−5.47 [−9.55, −1.39]; P = 0.009), LDL-cholesterol (−3.70 [−7.39, −0.00]; P = 0.05) and triglycerides (−16.44 [−25.64, −7.23]; P = 0.0005) when mean differences with 95% CI in the changes from baselines were meta-analyzed. In conclusion, GLP-1-based therapies appear to provide beneficial effects against atherosclerosis. More randomized data will be required to arrive at conclusive evidence.
format Online
Article
Text
id pubmed-4481643
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-44816432015-06-30 Anti-atherosclerotic effects of the glucagon-like peptide-1 (GLP-1) based therapies in patients with type 2 Diabetes Mellitus: A meta-analysis Song, Xiaoyan Jia, Hetang Jiang, Yuebo Wang, Liang Zhang, Yan Mu, Yiming Liu, Yu Sci Rep Article This study assessed the effect of GLP-1 based therapies on atherosclerotic markers in type 2 diabetes patients. 31 studies were selected to obtain data after multiple database searches and following inclusion and exclusion criteria. Age and BMI of the participants of longitudinal studies were 59.8 ± 8.3 years and 29.2 ± 5.7 kg/m(2) (Mean±SD). Average duration of GLP-1 based therapies was 20.5 weeks. Percent flow-mediated diameter (%FMD) did not change from baseline significantly but when compared to controls, %FMD increased non-significantly following GLP-1-based therapies (1.65 [−0.89, 4.18]; P = 0.2; REM) in longitudinal studies and increased significantly in cross sectional studies (2.58 [1.68, 3.53]; P < 0.00001). Intima media thickness decreased statistically non-significantly by the GLP-1 based therapies. GLP-1 based therapies led to statistically significant reductions in the serum levels of brain natriuretic peptide (−40.16 [−51.50, −28.81]; P < 0.0001; REM), high sensitivity c-reactive protein (−0.27 [−0.48, −0.07]; P = 0.009), plasminogen activator inhibitor-1 (−12.90 [−25.98, 0.18]; P=0.05), total cholesterol (−5.47 [−9.55, −1.39]; P = 0.009), LDL-cholesterol (−3.70 [−7.39, −0.00]; P = 0.05) and triglycerides (−16.44 [−25.64, −7.23]; P = 0.0005) when mean differences with 95% CI in the changes from baselines were meta-analyzed. In conclusion, GLP-1-based therapies appear to provide beneficial effects against atherosclerosis. More randomized data will be required to arrive at conclusive evidence. Nature Publishing Group 2015-06-26 /pmc/articles/PMC4481643/ /pubmed/26111974 http://dx.doi.org/10.1038/srep10202 Text en Copyright © 2015, Macmillan Publishers Limited http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
spellingShingle Article
Song, Xiaoyan
Jia, Hetang
Jiang, Yuebo
Wang, Liang
Zhang, Yan
Mu, Yiming
Liu, Yu
Anti-atherosclerotic effects of the glucagon-like peptide-1 (GLP-1) based therapies in patients with type 2 Diabetes Mellitus: A meta-analysis
title Anti-atherosclerotic effects of the glucagon-like peptide-1 (GLP-1) based therapies in patients with type 2 Diabetes Mellitus: A meta-analysis
title_full Anti-atherosclerotic effects of the glucagon-like peptide-1 (GLP-1) based therapies in patients with type 2 Diabetes Mellitus: A meta-analysis
title_fullStr Anti-atherosclerotic effects of the glucagon-like peptide-1 (GLP-1) based therapies in patients with type 2 Diabetes Mellitus: A meta-analysis
title_full_unstemmed Anti-atherosclerotic effects of the glucagon-like peptide-1 (GLP-1) based therapies in patients with type 2 Diabetes Mellitus: A meta-analysis
title_short Anti-atherosclerotic effects of the glucagon-like peptide-1 (GLP-1) based therapies in patients with type 2 Diabetes Mellitus: A meta-analysis
title_sort anti-atherosclerotic effects of the glucagon-like peptide-1 (glp-1) based therapies in patients with type 2 diabetes mellitus: a meta-analysis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4481643/
https://www.ncbi.nlm.nih.gov/pubmed/26111974
http://dx.doi.org/10.1038/srep10202
work_keys_str_mv AT songxiaoyan antiatheroscleroticeffectsoftheglucagonlikepeptide1glp1basedtherapiesinpatientswithtype2diabetesmellitusametaanalysis
AT jiahetang antiatheroscleroticeffectsoftheglucagonlikepeptide1glp1basedtherapiesinpatientswithtype2diabetesmellitusametaanalysis
AT jiangyuebo antiatheroscleroticeffectsoftheglucagonlikepeptide1glp1basedtherapiesinpatientswithtype2diabetesmellitusametaanalysis
AT wangliang antiatheroscleroticeffectsoftheglucagonlikepeptide1glp1basedtherapiesinpatientswithtype2diabetesmellitusametaanalysis
AT zhangyan antiatheroscleroticeffectsoftheglucagonlikepeptide1glp1basedtherapiesinpatientswithtype2diabetesmellitusametaanalysis
AT muyiming antiatheroscleroticeffectsoftheglucagonlikepeptide1glp1basedtherapiesinpatientswithtype2diabetesmellitusametaanalysis
AT liuyu antiatheroscleroticeffectsoftheglucagonlikepeptide1glp1basedtherapiesinpatientswithtype2diabetesmellitusametaanalysis